MediWound Ltd.

NASDAQ•MDWD

CEO: Mr. Ofer Gonen B.Sc.

セクター: Healthcare

業種: Biotechnology

上場日: 2014-03-20

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

連絡先情報

42 Hayarkon Street, Yavne, 8122745, Israel

972-7-797-14100

www.mediwound.com

時価総額

$180.10M

PER (TTM)

-8.9

17.9

配当利回り

52週高値

$22.51

52週安値

$14.14

52週レンジ

29%

順位51Top 71.3%

3.0

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$1.87M+0.00%

直近4四半期の推移

EPS

-$0.56+0.00%

直近4四半期の推移

フリーCF

-$5.23M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Decline in 2025 Total revenues $17.0M in 2025, down 15% from $20.2M in 2024, driven by lower Vericel sales and government shutdown delays.

Net Loss Reduction Net loss narrowed to $23.9M in 2025, showing improvement from $30.2M loss recorded in the prior fiscal year.

R&D Investment Surge R&D expenses increased 61% to $14.3M, primarily due to costs associated with the EscharEx VALUE Phase III clinical trial initiation.

Manufacturing Capacity Sixfold Expanded NexoBrid facility completed, achieving sixfold production capacity; commercial availability subject to 2026 regulatory approvals.

リスク要因

Clinical Development Uncertainty Pipeline product testing lengthy, expensive, with uncertain regulatory approval outcomes potentially causing significant delays.

Single Site Manufacturing Dependency Reliance on single manufacturing site in Yavne, Israel, vulnerable to accidents or force majeure events shutting down capacity.

Sole Supplier Supply Chain Key intermediate bromelain SP sourced from sole supplier located in Taiwan, posing supply chain continuity risks.

Geopolitical Operational Exposure Operations in Israel face direct impact from regional political instability and conflicts, potentially disrupting business continuity.

見通し

EscharEx Pivotal Trial Advancement Advance EscharEx through pivotal VALUE Phase III trial; peak sales opportunity estimated at $831M.

Sufficient Cash Runway Existing cash and deposits of $53.6M sufficient to fund operations and capital expenditure for at least twelve months.

NexoBrid Global Expansion Continue expanding NexoBrid commercial reach globally, targeting burn centers and potential use as BMCI countermeasure.

Future Capital Requirements Expect need to raise additional funding through debt or equity financing to support future growth and R&D activities.

同業比較

売上高 (TTM)

GNFT

$126.71M

+9.8%

CDXS

$70.39M

+18.6%

IVVD

$53.43M

+110.5%

粗利益率 (最新四半期)

GNFT

100.0%

+0.0pp

RNAC

100.0%

-2831.2pp

ASMB

100.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
SLS	$764.91M	-22.4	-95.2%	1.2%
GNFT	$445.68M	-10.9	-63.7%	64.1%
ASMB	$444.70M	-5.6	-59.0%	1.1%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-22.1%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月18日

EPS:-$0.60

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし